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ABSTRACT
BACKGROUND: A considerable number of patients with dilated cardiomyopathy (DCM) 
experience left ventricular reverse remodeling (LVRR). LV global longitudinal strain (LV GLS) 
offers sensitive and reproducible measurement of myocardial dysfunction. The authors sought 
to evaluate whether LV GLS at the time of diagnosis may predict LVRR in DCM patients with 
sinus rhythm and investigate its prognostic role in long-term follow-up in this population.
METHODS: We enrolled 160 DCM patients with sinus rhythm who had been initially 
diagnosed, evaluated, and followed at our institute. We analyzed their medical records and 
echocardiographic data.
RESULTS: During the mean follow-up duration of 37.3 ± 21.7 months, LVRR occurred in 28% of 
patients (n = 45). The initial LV ejection fraction (LVEF) of patients who recovered LV function 
was 26.1 ± 7.9%, which was not significantly different from the value of 27.1 ± 7.4% (p = 0.49) 
in those who did not recover. There was a moderate and highly significant correlation between 
baseline LV GLS (−%) and follow-up LVEF (r = 0.717; p < 0.001). Using multivariate Cox 
analysis, LV GLS (hazard ratio: 1.474, 95% confidence interval: 1.170-1.856; p = 0.001) was an 
independent predictor of LVRR.
CONCLUSIONS: We demonstrated that LV GLS was an independent predictor for LVRR and 
the optimal cut-off point of LV GLS for LVRR was −10% in DCM patients with sinus rhythm. 
There was a significant correlation between baseline LV GLS and follow-up LVEF.
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INTRODUCTION
Dilated cardiomyopathy (DCM) is one of the most common causes of heart failure and the 
most common indication for heart transplantation worldwide.1) Over the past few years, 
several studies have reported that 30% to 40% of patients with DCM can experience left 
ventricular reverse remodeling (LVRR). These findings imply that DCM does not represent 
an irreversible progressive pathway of myocardial failure but it is rather a dynamic disease 
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with non-linear progression.2)3) Many authors have reported that patients with a marked 
improvement in LV systolic function have excellent outcomes.2-4) Furthermore, the prediction of 
LV functional recovery is of clinical importance because it affects whether nonpharmacologic 
interventions such as cardiac transplantation, LV assist device, implantable cardioverter-
defibrillator (ICD), and cardiac resynchronization therapy are needed.
Left ventricular ejection fraction (LVEF) is the most widely used parameter for assessing 
cardiac function and is a predictor of outcomes. However, it has several intrinsic limitations 
including late decrease only in the advanced stage of heart disease, poor reliability in patients 
with LV hypertrophy and volume reduction, relatively poor inter-observer and intra-observer 
variability, and difficult endocardial border detection.
Recent studies have reported that LV global longitudinal strain (GLS) is a more sensitive 
measure of myocardial dysfunction and is more reproducible than LVEF. Additionally, it is a 
more powerful predictor of outcomes in patients with heart failure with a reduced ejection 
fraction.5)6) Most previous studies regarding LVRR in patients with DCM also included 
patients with atrial fibrillation (AF). However, it is difficult to accurately measure the value 
of strain by two-dimensional (2D) speckle tracking because of beat-to-beat variation. 
Furthermore, the LV GLS value is inconsistent. In this study, we aimed to determine whether 
LV GLS at the time of diagnosis may predict LVRR and to investigate the prognostic role of LV 
GLS in long-term follow-up in DCM patients with sinus rhythm. Additionally, we evaluated 
the prognostic role of LV GLS in long-term follow-up in this population. To the best of our 
knowledge, there are no previous reports regarding the association between initial LV GLS 
and recovery of LV systolic function in DCM patients with sinus rhythm.
METHODS
Study population
We designed this study as a retrospective analysis. Therefore, we reviewed medical records 
of 442 patients with heart failure who had been initially diagnosed, evaluated, and followed 
at Sanggye Paik Hospital, Inje University College of Medicine between March 2013 and 
February 2018. The diagnosis of DCM was established on the basis of the following criteria: 
(i) presence of LV dilation (LV end-diastolic diameter ≥ 55 mm); (ii) presence of reduced LV 
ejection fraction (EF) (all ≤ 45%); (iii) coronary angiographic evidence of absence of coronary 
artery disease defined as > 50% stenosis of a major epicardial vessel or a history of myocardial 
infarction; and (iv) absence of cardiac muscle disease secondary to any known systemic 
disease.7) As shown in Figure 1, patients who received cardiac resynchronization therapy (1), 
pacemaker (17), implantable cardioverter defibrillator (3), or obtained an LV assist device 
were excluded. We also excluded patients with AF (118), other major cardiac arrhythmias, 
pulmonary thromboembolism, idiopathic pulmonary hypertension, hyperthyroidism, more 
than moderate organic valvular disease except functional mitral regurgitation (MR), and 
stage 4 or more advanced renal failure or end-stage renal disease requiring renal replacement 
therapy. We excluded 67 patients who had difficulty in analysis due to poor image on 
echocardiography or follow-up loss. In total, 160 patients were enrolled in this study. The 
subjects were in clinically stable condition at the time of enrollment in this study and were 
undergoing optimal and maximally-tolerated pharmacological therapy. This study complied 
with the Declaration of Helsinki, and the local ethics committee approved the research 
protocol. The requirement of informed consent was waived by the committee.
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Definition of LVRR
LVRR was defined as the combined presence of: 1) an increase in LVEF of at least 10% points 
or a follow-up LVEF ≥ 50% (in patients with an LVEF of 40% to 45% at enrolment); and 2) 
a decrease in indexed left ventricular end-diastolic diameter (LVEDDI) of at least 10% or an 
LVEDDI ≤ 33 mm/m2.2)3)
Echocardiography
A standardized complete echocardiographic examination was performed at baseline and 
during follow-up according to the standard method outlined by the American Society of 
Echocardiography.8) 2D echocardiographic images were obtained using VIVID E9 and E95 
(General Electric Medical Systems, Horten, Norway). All conventional echocardiographic 
parameters were measured and averaged over three cardiac cycles. All echocardiographic data 
were reanalyzed with commercially available software (EchoPAC PC software, GE Medical 
Systems, Horten, Norway).
Significant functional MR should fulfill all of the following three criteria: 1) normal mitral 
valve leaflets and chords, 2) regional or global wall motion abnormalities of LV with tethering 
of the leaflet, and 3) MR of EROA > 0.1 cm2.9)
2D-speckle tracking measurements of LV GLS were performed in the 2-, 3-, and 
4-chamber apical views and aortic valve closure was used for timing of end-systole.10) The 
endocardial border was traced manually at end-systole. Tracking was adjusted to include 
the entire myocardial wall from the endocardium to the myoepicardial border. All LV GLS 
measurements were performed by a single investigator (J. H. Park), with all the images 
reviewed and validated by a second reader. Reproducibility was performed on a single set 
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442 patients with DCM
115 patients without LVRR 45 patients with LVRR
160 were included in the analysis
TTE image of 227 patients were evaluated 
215
118
1
3
17
29
42
5
were excluded
had AF
had received CRT-D
had received ICD 
had received PPM
had significant VHD
had CKD ≥ stage 4
had PTE, hyperthyroidism, i-PHT
67
21
35
11
were excluded 
poor image
no annual TTE (12 ± 6 months)
follow-up loss
Figure 1. Study flow chart. AF: atrial fibrillation, CKD: chronic kidney disease, CRT: cardiac resynchronization 
therapy, DCM: dilated cardiomyopathy, ICD: implantable cardioverter defibrillator, i-PHT: idiopathic pulmonary 
hypertension, LVRR: left ventricular reverse remodeling, PPM: permanent pacemaker, PTE: pulmonary 
thromboembolism, TTE: transthoracic echocardiography, VHD: valvular heart disease.
of recordings. Variability in the measurement of LV GLS was evaluated in 20 randomly 
selected patients. To determine intra-observer and inter-observer variability, the investigator 
measured GLS for each of the selected patients again 2 weeks later. The coefficients of 
variation of intra- and inter-observer variability for GLS measurements were less than 5%.
Conventional echocardiographic parameters indicating right ventricular (RV) systolic 
function were measured in a standard manner according to the guidelines of Rudski et al.11) 
The RV fractional area change was calculated using the percent area change of the end-
diastolic and end-systolic areas of the RV in the apical four-chamber views. Tricuspid annular 
plane systolic excursion was measured as the contraction distance of the RV tricuspid annular 
plane along its longitudinal plane during systole.
Follow-up for echocardiography and clinical course
There were two different temporal perspectives in this study. One was to see whether 
LVRR occurred and the other was to see whether an adverse clinical event occurred. First, 
echocardiographic evaluation was scheduled to be performed annually after diagnosis of 
DCM, and the mean interval of echocardiography in these patients was 10.7 ± 7.3 months. 
The interval of echocardiography in patients without LVRR was shorter than in patients with 
LVRR (9.5 ± 6.4 vs. 13.7 ± 8.8 months, p = 0.027). We analyzed the echocardiographic data at 
the time DCM was initially diagnosed. Additionally, follow-up echocardiographic data were 
collected. For patients with LVRR, the results of echocardiography at the time of recovery 
were analyzed, and for patients who were not recovered, the results of the last performed 
tests were analyzed. Second, we collected clinical follow-up data for occurrence of adverse 
clinical events. We recorded the date of last follow-up in patients without adverse events and 
recorded the date of occurrence of events in patients with events.
Adverse clinical events were defined as all-cause death, death from, cardiac transplantation 
or hospitalization for deteriorating heart failure, and major ventricular arrhythmias or 
aborted sudden cardiac death. Major ventricular arrhythmias were considered as ventricular 
fibrillation/flutter or a sustained ventricular tachycardia (hemodynamically unstable or 
lasting more than 30 seconds) or appropriate ICD intervention. Long-term follow-up was 
conducted for 37.3 ± 21.7 months (patients with LVRR vs. without LVRR, 38.1 ± 27.8 vs. 37.0 ± 
19.4 months, p = 0.855).
Statistical analysis
Continuous variables with a normal distribution were expressed as mean ± standard deviation 
or percentages. The parameters of the two subgroups, patients with and without LVRR, were 
compared using unpaired Student's t-test or Mann-Whitney U test for continuous variables. 
The χ2 tests (or Fisher's exact tests when any expected count was < 5 for a 2 × 2 table) was used 
for categorical variables. To evaluate change from baseline, a paired Student's t-test was used. 
Pearson's correlation was used to calculate the association between baseline LV GLS and 
follow-up LVEF. We performed a time-to-event analysis using a univariate Cox proportional-
hazards model for all patients to determine the independent factors influencing LVRR. 
Variables with a univariate value of p < 0.05 were incorporated into the stepwise selection, 
while age, sex, medications, and LV dimensions expected to be highly associated with LVRR 
were forced into the multivariate analysis regardless of its association on univariate analysis. 
The receiver-operating characteristic (ROC) curve was constructed to determine the optimal 
cut-off values of LV GLS for LVRR. We then divided the subjects into two groups based on the 
cut-off value. Kaplan-Meier curve analysis was conducted to assess cardiovascular event-free 
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survival during the follow-up period and compared it by using log-rank test. A probability 
value of p < 0.05 was considered significant. All statistical analyses were performed using 
SPSS software package (version 25, IBM SPSS Statistics, Chicago, IL, USA).
RESULTS
Baseline characteristics
A total of 160 patients who fulfilled all inclusion and exclusion criteria were enrolled. The 
mean age was 64.5 years, and 67.5% were male. Forty-five patients (28%) experienced 
LVRR within 14.7 ± 10.0 months after medical therapy. Clinical parameters are summarized 
in Table 1. As compared with patients who did not develop LVRR, patents with LVRR 
had fewer left bundle branch blocks (LBBB) and more dyslipidemia, and more patients 
used statins. However, no significant differences between the subgroups were noted in 
terms of age, gender distribution, body mass index, or blood pressures. A comparison of 
echocardiographic data between patients with LVRR and those without LVRR is shown in 
Table 2. The initial LVEF of patients who recovered LV function was 26.1 ± 7.9%, which was 
not significantly different from the value of 27.1 ± 7.4% (p = 0.49) for those who did not 
recover LV function. However, patients with LVRR had a larger LV, smaller left atrium (LA), 
and more frequent significant functional MR than those who did not have LVRR. The E/e′ 
ratio was higher and the values of LV GLS were lower in patients without LVRR.
Comparison of baseline and follow-up echocardiography parameters
Follow-up LV functional echocardiographic parameters of all patients were improved when 
compared with baseline data except for the LVEF (27.8 ± 7.4%, ΔLVEF of 0.7%, p = 0.126) of 
patients without LVRR (Table 3). Patients with LVRR had a final LVEF of 49.4 ± 9.5% (ΔLVEF 
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Table 1. Baseline clinical characteristics
All patients (n = 160) Patients without LVRR (n = 115) Patients with LVRR (n = 45) p-value
Age (years) 64.5 ± 14.9 65.6 ± 14.9 61.9 ± 14.6 0.166
Male sex 108 (67.5) 78 (67.8) 30 (66.7) 1.000
BSA (m2) 1.8 ± 0.5 1.9 ± 0.6 1.7 ± 0.2 0.064
BMI (kg/m2) 24.5 ± 4.2 24.4 ± 4.3 24.7 ± 4.2 0.681
Systolic BP (mmHg) 125.0 ± 19.8 124.3 ± 21.8 125.5 ± 16.2 0.859
Diastolic BP (mmHg) 76.7 ± 13.0 76.7 ± 13.9 76.9 ± 10.1 0.937
Heart rate (bpm) 76.9 ± 16.4 77.5 ± 16.7 75.9 ± 10.1 0.499
LBBB 26 (16.3) 23 (20.0) 3 (6.7) 0.040
Comorbidities
Hypertension 71 (44.4) 46 (40.0) 25 (55.6) 0.075
Diabetes mellitus 50 (31.3) 37 (32.2) 13 (28.9) 0.687
Dyslipidemia 62 (38.8) 38 (33.0) 24 (53.3) 0.018
CKD
Normal to stage 1 137 (85.6) 96 (83.5) 41 (91.1) 0.454
Stage 2 16 (10.0) 13 (11.3) 3 (6.7) 0.454
Stage 3 7 (4.4) 6 (5.2) 1 (2.2) 0.454
Smoking 36 (22.5) 26 (22.6) 10 (22.2) 0.958
Medication
ACE-I/ARBs 132 (82.5) 91 (79.1) 41 (91.1) 0.073
β-Blockers 99 (61.9) 71 (61.7) 28 (62.2) 0.955
Ivabradine 61 (38.1) 44 (38.2) 17 (37.8) 0.955
MRA 84 (52.5) 64 (55.7) 20 (44.4) 0.202
Statin 72 (45.0) 46 (40.0) 26 (57.8) 0.042
Data are presented as mean ± SD, n (%), or median (inter-quartile range).
ACE-I: angiotensin-converting enzyme-inhibitor, ARB: angiotensin II receptor blocker, BMI: body mass index, BP: blood pressure, BSA: body surface area, CKD: 
chronic kidney disease, LBBB: left bundle branch block, LVRR: left ventricular reverse remodeling, MRA: mineralocorticoid receptor antagonist.
of 23.9%, p < 0.001) and had a significant decrease in LVEDDI (29.8 ± 5.2 mm/m2; ΔLVEDDI 
of 7.5 mm/m2, p < 0.001) as well as an increase in the absolute value of LV GLS (16.9 ± 2.7%; 
ΔLV GLS of 5.1%, p < 0.001). The mean differences of the LV GLS between baseline and 
follow-up in patients were 0.5 ± 1.3% for patients without LVRR (Figure 2A) and 5.1 ± 2.9% 
for patients with LVRR (Figure 2B).
Correlation between baseline LV GLS and follow-up echocardiographic 
parameters
Baseline LV GLS had a significant negative correlation between follow-up LV dimensions 
and positive correlation with follow-up LVEF and Δ EF (i.e., difference between baseline and 
follow-up LVEF) (Table 4). Although baseline LV GLS was widely distributed at the follow-up 
LVEF levels, there was a moderate and highly significant correlation between baseline LV GLS 
and follow-up LVEF (r = 0.717; p < 0.001) (Figure 3).
Adverse events
During follow-up, 25 patients (15.6%) had serious adverse events including 3 cardiac deaths 
and 1 cardiac transplantation. Among patients without LVRR, 13 patients were admitted for 
worsening heart failure, and 4 patients experienced major ventricular arrhythmia or aborted 
sudden cardiac death. In the group that recovered LV function, there were 2 patients who 
were admitted for worsening heart failure and 2 patients who experienced major arrhythmia, 
but there were no deaths (Table 5). There was no significant difference in the incidence of 
adverse events between the two groups (p = 0.142).
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Table 2. Baseline echocardiographic characteristics
All patients (n = 160) Patients without LVRR (n = 115) Patients with LVRR (n = 45) p-value
LV functional parameters
LVEDDI (mm/m2) 35.6 ± 6.6 34.9 ± 6.8 37.4 ± 5.5 0.028
LVESDI (mm/m2) 30.3 ± 6.1 29.5 ± 6.1 32.2 ± 5.7 0.012
LVEDVI (mL/m2) 95.0 ± 30.7 92.0 ± 30.5 102.7 ± 30.2 0.047
LVESVI (mL/m2) 70.0 ± 24.8 67.1 ± 24.4 77.3 ± 24.5 0.020
LVEF (%) 26.8 ± 7.5 27.1 ± 7.4 26.1 ± 7.9 0.489
LV GLS (−%) 9.2 ± 3.1 8.2 ± 2.9 11.9 ± 1.6 < 0.001
Transmitral flow parameters
E wave velocity (cm/s) 60.1 ± 24.1 64.6 ± 25.3 49.2 ± 16.5 < 0.001
A wave velocity (cm/s) 69.7 ± 24.6 68.6 ± 26.5 72.4 ± 19.5 0.396
E/A ratio (medial) 1.4 ± 5.3 1.7 ± 6.3 0.7 ± 0.4 0.291
Tissue Doppler parameters
Septal s′ (cm/s) 4.9 ± 1.4 4.6 ± 1.3 5.8 ± 1.3 < 0.001
Septal e′ (cm/s) 4.2 ± 1.6 3.9 ± 1.5 4.9 ± 1.7 < 0.001
Septal a′ (cm/s) 7.2 ± 5.2 6.1 ± 0.6 8.0 ± 1.7 0.229
E/e′ ratio 15.9 ± 9.7 17.9 ± 10.4 10.8 ± 4.5 < 0.001
LAVI (mL/m2) 28.8 ± 11.3 31.5 ± 11.4 21.8 ± 7.5 < 0.001
Significant MR 24 (20.9) 18 (40.0) 0.013
RV functional parameters
RV s′ velocity (cm/s) 10.6 ± 2.5 10.5 ± 2.7 10.8 ± 2.3 0.563
TRVmax (m/s) 2.5 ± 0.6 2.5 ± 0.6 2.4 ± 0.5 0.138
TAPSE (mm) 1.9 ± 0.4 1.9 ± 0.4 1.9 ± 0.3 0.958
RVFAC (%) 42.1 ± 10.5 42.1 ± 11.3 42.2 ± 8.2 0.956
Data are presented as mean ± SD, n (%), or median (inter-quartile range).
LAVI: left atrial volume index, LV: left ventricular, LV GLS: LV global longitudinal strain, LVEDDI: LV end-diastolic diameter index, LVEDVI: LV end-diastolic volume 
index, LVEF: LV ejection fraction, LVESDI: LV end-systolic diameter index, LVESVI: LV end-systolic volume index, LVRR: left ventricular reverse remodeling, MR: 
mitral regurgitation, RV: right ventricular, RVFAC: RV fractional area change, TAPSE: tricuspid annular plane systolic excursion, TRVmax: tricuspid regurgitation 
jet maximum velocity.
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Table 3. Comparison of baseline and follow-up LV functional echocardiographic data
Baseline Follow-up Difference (95% CI) p-value
All patients (n = 160)
LVEDDI (mm/m2) 35.6 ± 6.6 32.9 ± 6.6 −2.7 (−3.4 to −2.0) < 0.001
LVESDI (mm/m2) 30.3 ± 6.1 26.6 ± 6.6 −3.7 (−4.6 to −2.8) < 0.001
LVEDVI (mL/m2) 95.0 ± 30.7 74.3 ± 30.2 −20.7 (−25.6 to −15.8) < 0.001
LVESVI (mL/m2) 70.0 ± 24.8 50.2 ± 26.8 −19.8 (−24.2 to −15.4) < 0.001
LVEF (%) 26.8 ± 7.5 33.9 ± 12.6 7.2 (5.2 to 9.2) < 0.001
LV GLS (−%) 9.2 ± 3.1 11.0 ± 4.8 1.8 (1.3 to 2.2) < 0.001
Patients without LVRR (n = 115)
LVEDDI (mm/m2) 34.9 ± 6.8 34.1 ± 6.8 −0.8 (−1.3 to −0.3) 0.002
LVESDI (mm/m2) 29.5 ± 6.1 28.4 ± 6.4 −1.4 (−1.8 to −0.4) 0.002
LVEDVI (mL/m2) 92.0 ± 30.5 83.4 ± 29.8 −8.6 (−12.4 to −4.8) < 0.001
LVESVI (mL/m2) 67.1 ± 24.4 59.5 ± 25.3 −7.6 (−10.9 to −4.3) < 0.001
LVEF (%) 27.1 ± 7.4 27.8 ± 7.4 0.7 (−0.2 to 1.6) 0.126
LV GLS (−%) 8.2 ± 2.9 8.7 ± 3.2 0.5 (0.7 to 3.6) < 0.001
Patients with LVRR (n = 45)
LVEDDI (mm/m2) 37.4 ± 5.5 29.8 ± 5.2 −7.5 (−9.1 to −6.0) < 0.001
LVESDI (mm/m2) 32.2 ± 5.7 21.9 ± 4.4 −10.3 (−11.9 to −8.6) < 0.001
LVEDVI (mL/m2) 102.7 ± 30.2 51.1 ± 15.0 −51.7 (−61.6 to −41.7) < 0.001
LVESVI (mL/m2) 77.3 ± 24.5 26.4 ± 11.3 −50.9 (−58.8 to −43.1) < 0.001
LVEF (%) 26.1 ± 7.9 49.4 ± 9.5 23.9 (20.4 to 27.5) < 0.001
LV GLS (−%) 11.9 ± 1.6 16.9 ± 2.7 5.1 (4.2 to 5.9) < 0.001
Data are presented as mean ± SD, n (%), or median (inter-quartile range).
CI: confidence interval, LV: left ventricular, LV GLS: LV global longitudinal strain, LVEDDI: LV end-diastolic diameter index, LVEDVI: LV end-diastolic volume index, 
LVEF: LV ejection fraction, LVESDI: LV end-systolic diameter index, LVESVI: LV end-systolic volume index, LVRR: left ventricular reverse remodeling.
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Figure 2. Changes in LV GLS of the patients without LVRR (A) and with LVRR (B). The mean difference of LV GLS 
between baseline and follow-up in both groups were significant; however, LV GLS was more prominent in patients 
with LVRR. The mean of differences of LV GLS (−%) of patients without LVRR vs. with LVRR were 0.5 ± 1.3% vs. 5.1 
± 2.9% (p < 0.001). LV GLS: left ventricular global longitudinal strain, LVRR: left ventricular reverse remodeling.
Table 4. Correlation between baseline LV GLS and follow-up echocardiographic parameters
Echocardiographic parameters r p-value
Follow-up LVEDDI −0.515 < 0.001
Follow-up LVESDI −0.612 < 0.001
Follow-up LVEDVI −0.572 < 0.001
Follow-up LVESVI −0.639 < 0.001
Follow-up LVEF 0.717 < 0.001
Δ EF 0.376 < 0.001
LV: left ventricular, LV GLS: LV global longitudinal strain, LVEDDI: LV end-diastolic diameter index, LVEDVI: LV 
end-diastolic volume index, LVEF: LV ejection fraction, LVESDI: LV end-systolic diameter index, LVESVI: LV end-
systolic volume index, r: correlation coefficient, Δ EF: difference between baseline and follow-up LVEF.
Predictor for LVRR
The hazard ratio (HR) of each variable is shown in Table 6. By univariate analysis using a Cox 
proportional hazard model, no LBBB, higher value of LV GLS (−%), lower LA volume index, 
and E/e′ ratio were significantly associated with LVRR. Using multivariate Cox analysis, LV 
GLS (HR: 1.474, p = 0.001) was an independent predictor of LVRR in DCM patients with 
sinus rhythm. Among the medications, ACE-I/ARB was not a valid variable for LVRR in 
univariate analysis (HR: 1.686, p = 0.332), but it was a significant variable in multivariate 
analysis (HR: 4.031, p = 0.029).
LVRR and adverse clinical events
The survival curves of the study population classified according to LVRR are shown in Figure 4A.  
DCM patients with LVRR had a significantly better long-term prognosis with respect to the 
others (Log-rank test, p = 0.029).
By analyzing the ROC curve, LV GLS ≤ −10% was selected as the best cut-off value to 
discriminate between patients with and without LVRR with 98% sensitivity and 63% 
specificity (area under the curve = 0.854, p < 0.001). However, patients with LV GLS ≤ −10% 
was not lower in occurrence of adverse event compared to those with LV GLS > −10% (Log-
rank test, p = 0.086) when we divided the subjects into two groups based on the cut-off value 
for LV GLS of −10% (Figure 4B).
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Figure 3. There was a moderate but highly significant correlation (r = 0.717, p < 0.001) between baseline LV GLS 
and follow-up LVEF. LV GLS: left ventricular global longitudinal strain, LVEF: left ventricular ejection fraction.
Table 5. Events in the patients with LVRR compared with the patients without LVRR
All patients (n = 160) Patients without LVRR (n = 115) Patients with LVRR (n = 45) p-value
Events 25 (15.6) 21 (18.3) 4 (8.9) 0.142
Hospitalization for worsening HF 15 (9.4) 13 (11.3) 2 (4.4) NS
MVA or aborted SCD 6 (3.8) 4 (3.5) 2 (4.4) NS
Death or heart transplantation 4 (2.5) 4 (3.5) 0 (0) NS
Data are presented as n (%).
HF: heart failure, LVRR: left ventricular reverse remodeling, MVA: major ventricular arrhythmia, SCD: sudden cardiac death.
DISCUSSION
In this study, we showed that LV GLS is an independent predictive factor for LVRR in DCM 
patients with sinus rhythm. Even though the LV of the patients with LVRR was more dilated 
and LVEF was similar compared with those without LVRR on baseline echocardiographic 
data, the absolute value of LV GLS was higher in patients who experienced a reverse LV 
remodeling. Additionally, we demonstrated a significant correlation between baseline LV 
GLS and follow-up LVEF in DCM patients with sinus rhythm. Recent studies have shown that 
tailored medical therapy can lead to a reverse LV remodeling and improve LVEF resulting in 
reduced heart failure morbidity and mortality.3)4)12)13) In the present study, LVRR occurred in 
28% of DCM patients, and the long-term prognosis of patients with LVRR was better than 
those without LVRR. These results are similar to those reported by other investigators.
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Table 6. Cox regression analysis for LV reverse remodeling
Variables Univariate analysis Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
Age 0.993 0.973–1.013 0.465 1.000 0.974–1.026 0.974
Female sex 1.054 0.567–1.959 0.869 0.859 0.380–1.944 0.716
LBBB 5.066 1.567–16.376 0.007 1.808 0.519–6.300 0.352
ACE-I/ARBs 1.686 0.586–4.849 0.332 4.031 1.155–14.075 0.029
β-Blockers 1.285 0.188–1.927 0.337 1.692 0.839–3.697 0.173
Ivabradine 0.579 0.290–1.159 0.123 1.328 0.147–1.733 0.107
MRA 1.273 0.705–2.297 0.423 1.607 0.869–3.196 0.136
LVEDDI 0.994 0.948–1.042 0.798 1.329 0.985–1.792 0.062
LVESDI 0.993 0.944–1.045 0.782 0.689 0.494–0.960 0.028
LVEF 0.972 0.928–1.018 0.227 1.058 0.983–1.240 0.178
LV GLS 1.411 1.240–1.605 <0.001 1.474 1.170–1.856 0.001
LA volume index 0.918 0.880–0.957 <0.001 0.966 0.922–1.012 0.143
E/e′ ratio 0.921 0.874–0.971 0.002 0.958 0.890–1.031 0.255
Significant MR 0.851 0.466–1.551 0.598
RV FWLS 1.002 0.959–1.048 0.919
ACE-I: angiotensin-converting enzyme-inhibitor, ARB: angiotensin II receptor blocker, CI: confidence interval, GLS: global longitudinal strain, HR: hazard ratio, 
LA: left atrium, LBBB: left bundle branch block, LV: left ventricular, LVEDDI: LV end-diastolic diameter index, LVEF: LV ejection fraction, LVESDI: LV end-systolic 
diameter index, MR: mitral regurgitation, MRA: mineralocorticoid receptor antagonist, RV: right ventricular, RV FWLS: RV free-wall longitudinal strain.
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Figure 4. Kaplan-Meier curves for event-free survival according to the patients with and without LVRR (A), and two groups divided by LV GLS of −10% (B). LV GLS: 
left ventricular global longitudinal strain, LVRR: left ventricular reverse remodeling.
It was our principal finding that LVRR occurred more frequently in patients with better LV 
GLS values of LV GLS even with similar LVEF. LV global strain is an accurate and sensitive 
measure of myocardial deformation, allowing for angle-independent quantification 
of myocardial function in 2D based on the LV active shortening in the longitudinal, 
circumferential, and radial directions. which is more reproducible than EF and does not 
rely on geometrical assumptions.14) Among the LV global strains, LV GLS has been shown 
to be more reproducible and more useful clinically than circumferential strain (GCS) and 
radial strains.15)16) Furthermore, LV GLS reflects the contraction of the subendocardial layer, 
which is mainly longitudinally oriented. It is well established that the longitudinal cardiac 
fibers located in the subendocardium are the first to be affected by myocardial injury.17) The 
absolute value of LV GLS had significant negative correlation with subendocardial percentage 
area fibrosis in a rat model of hypertensive heart failure with preserved LVEF.18) A recent 
study demonstrated that LV GLS has a significant association with cardiovascular events in 
patients with acute heart failure, but GCS and twist value did not.19) DCM is associated with 
increase in collagen content, and the excessive extracellular matrix turnover may contribute 
to adverse LV remodeling and poor prognosis.20) The degree of myocardial fibrosis may be 
associated with reversibility in ventricular function in DCM. The gold standard in clinical 
practice for in-vivo tissue characterization is late gadolinium enhancement (LGE) detected by 
cardiac magnetic resonance (CMR); it has been shown to be a reliable method for detecting 
and quantifying myocardial fibrosis, a pathological expansion of the myocardial interstitium 
that is a common manifestation of most advanced cardiomyopathies with major prognostic 
implications.21-23) Therefore, LGE is associated with functional recovery of DCM, and the 
smaller the area of LGE is, the better result for reverse LV remodeling. Several studies have 
demonstrated an association between LV GLS and areas of LGE by CMR.24) Our study showed 
that LV GLS is an independent predictor for functional recovery of DCM, and this result 
supports previous findings that the greater the area of myocardial fibrosis, the lower the 
likelihood of recovery of LV function.
Similar to previous studies, good clinical outcomes were observed in patients with LVRR 
compared with those without LVRR in this study. In addition, we demonstrated that the 
optimal cut-off point of LV GLS for reverse LV remodeling was −10%. In our population, 
in which LV systolic function was already reduced, there was a relatively small difference 
in LV GLS between patients with and without LVRR. Although there is a highly significant 
correlation between LVEF and LV GLS, a recent study showed that the values of LV GLS 
in patients with acute heart failure could be distributed widely at any given LVEF level. 
The study's results demonstrated that every 1% decrease in LV GLS was associated with 
a 5% increased risk for death after adjustment for significant covariates.19) Therefore, we 
speculated that this subtle difference could affect the recovery of LV function in patients with 
heart failure. However, we failed to show differences in the event-free survival rate between 
groups based on the LV GLS cut-off value of −10% for LVRR. We believe that this outcome is 
likely a result of the events rate being relatively low in the subjects of this study, as described 
in the study limitation below.
The LA size of our DCM patients was relatively small compared with the population of 
other studies, and the number of patients with LVRR was smaller than that of those without 
LVRR. LA size and volume serve as good predictors for clinical outcomes in patients with 
heart failure, because they correlate well with the severity and chronicity of LV diastolic 
dysfunction.25) Furthermore, LA enlargement is associated with poor clinical outcomes 
in DCM patients.26)27) Because of the larger LA and LV sizes, more severe functional MR 
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correlates with more AF. However, we excluded patients with AF, because AF per se may cause 
impairment of LV systolic dysfunction; AF is not only the most common arrhythmia in heart 
failure, but it also causes heart failure. Moreover, ventricular filling may be impaired because 
of loss of active atrial contraction and shortening of the diastolic time in patients with AF, 
resulting in a 15%–20% reduction of cardiac output.28-30) Additionally, paroxysmal tachycardia 
is frequent in AF patients and may lead to systolic impairment through a mechanism 
characterized by tachycardia-induced cardiomyopathy, resulting in a further decrease in 
cardiac output. Therefore, we cannot be certain regarding the initial cause in the relationship 
between AF and heart failure. Furthermore, it is difficult to accurately measure the value of 
strain by 2D speckle tracking because of the beat-to-beat variation.
Study limitations
The present study has several limitations. First, this was a single-center observational study 
of subjects who were registered in our institute and was performed using a single vendor-
specific software. Therefore, our study group may not represent all patients with DCM, and 
our results may not apply to other equipment. Second, only 61.9% of patients enrolled in 
our study used beta-blockers, which was significantly lower than that reported in previous 
studies. At the time of enrollment in this study, it is possible that many of the patients with 
DCM had low blood pressure. And this reason forced them to use a combination of low dose 
beta blocker and ivabradine (25 patients without LVRR vs. 9 with LVRR, 21.7% vs. 20.0%) but 
often use ivabradine alone for patients who cannot tolerate beta blocker (19 patients without 
LVRR vs. 8 with LVRR, 16.5% vs. 17.8%). However, there was no significant difference 
between the two groups in the frequency of ivabradine alone or beta blocker combination (p 
= 0.785). Furthermore, Cox regression multivariate analysis revealed that ACE-i / ARB, rather 
than beta blockers or ivabradine, had a significant effect on the occurrence of LVRR in this 
study population. Third, the number of patients with cardiovascular events was relatively 
small, although the mean follow-up period of about 40 months was adequate. This is likely 
because we excluded subjects with AF and enrolled a relatively small number of patients 
with significant MR; AF and MR are considered important prognostic factors for clinical 
outcomes in DCM patients. We think this is one of the reasons why we failed to demonstrate 
the differences of event-free survival rate between groups based on the cut-off value of LV 
GLS for LVRR. Finally, because LV GLS values are highly correlated with LVEF, the difference 
in LV GLS values between patients who have already reduced LVEF, such as DCM patients, is 
not numerically large. We suggest that these results disprove that LV GLS is a more objective 
indicator than LVEF in patients with DCM; however, it would be inappropriate to predict 
the prognosis or a recovery of LV function in DCM patients based on only the LV GLS value. 
Nevertheless, in this study we showed that recovery of LV function occurred more frequently 
when DCM patients had better LV GLS values, even in patients with similar LVEF, which was 
significantly reduced at the time of diagnosis.
Conclusions
In our single-center study, we demonstrated that LV GLS was an independent predictor for 
LVRR, and the optimal cut-off point of LV GLS for LVRR was −10% in DCM patients with 
sinus rhythm. Patients with LVRR showed a significantly better long-term prognosis than 
those without LVRR. There was a significant correlation between baseline LV GLS and follow-
up LVEF in this population. Therefore, we suggest LV GLS should be measured in DCM 
patients with sinus rhythm at the time of initial diagnosis. To validate the role of LV GLS 
in LVRR and prognosis in DCM patients with sinus rhythm, however, future studies must 
include long-term data compiled from a larger patient population.
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